{"id":974581,"date":"2026-06-23T07:04:04","date_gmt":"2026-06-23T11:04:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-appoints-ron-philip-to-board-of-directors\/"},"modified":"2026-06-23T07:04:04","modified_gmt":"2026-06-23T11:04:04","slug":"avalo-therapeutics-appoints-ron-philip-to-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-appoints-ron-philip-to-board-of-directors\/","title":{"rendered":"Avalo Therapeutics Appoints Ron Philip to Board of Directors"},"content":{"rendered":"
\n

WAYNE, Pa., June 23, 2026 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1\u03b2 pathway for immune-mediated inflammatory diseases, today announced the appointment of Ron Philip to its Board of Directors. Mr. Philip brings more than 30 years of biopharmaceutical leadership to the Board, with a deep background in commercial and strategic execution, including guiding multiple companies through product launches and billion dollar exits.<\/p>\n

\u201cWe are thrilled to welcome Ron to the Board at this pivotal time for Avalo following our positive Phase 2 LOTUS topline results and transformative financing,\u201d said Garry Neil, MD, Chief Executive Officer of Avalo Therapeutics. \u201cRon\u2019s strategic and commercial expertise, including his proven success bringing novel therapies to market, will be invaluable as we advance abdakibart in hidradenitis suppurativa (HS) into phase 3 and beyond. We look forward to his guidance as we work to deliver this important therapy to patients.\u201d<\/p>\n

\u201cI am excited to join Avalo\u2019s Board following the compelling Phase 2 topline data for abdakibart in HS, which highlight its potential to become a best-in-disease treatment,\u201d said Ron Philip. \u201cThe trial demonstrated potential leading efficacy, a favorable safety profile, and the convenience of monthly dosing, attributes that are the cornerstones of a successful commercial product. I look forward to sharing my experience to help shape the strategic and commercial plan and ultimately bring this differentiated new treatment option to the HS community.\u201d<\/p>\n

Mr. Philip currently serves as Executive Chair of CREATE Medicines. Previously, he served as Chief Executive Officer of Orbital Therapeutics, where he led the company through its $1.5 billion acquisition by Bristol Myers Squibb. Prior to Orbital, Mr. Philip held a series of senior leadership positions at Spark Therapeutics, ultimately serving as Chief Executive Officer. Earlier, he served as Chief Operating Officer and Chief Commercial Officer, leading the commercial launch of LUXTURNA\u00ae, Spark\u2019s first FDA-approved gene therapy and the first gene therapy approved in the United States for a genetic disease. During his tenure, he also played a key leadership role in Spark\u2019s $4.8 billion acquisition by Roche. Earlier in his career, Mr. Philip held senior strategy, commercial, and operational leadership roles at Pfizer and Wyeth, where he supported several successful medicines, including ENBREL\u00ae and XELJANZ\u00ae. He currently serves on the boards of Harmony Biosciences and City Therapeutics. Mr. Philip is a graduate of Drexel University.<\/p>\n

\n About Avalo Therapeutics<\/strong>\n <\/p>\n

Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1\u03b2 pathway for immune-mediated inflammatory diseases. Our lead asset, abdakibart, is an anti-IL-1\u03b2 monoclonal antibody (mAb). Positive topline data was recently reported for abdakibart in a Phase 2 clinical trial in hidradenitis suppurativa (HS). In addition to HS, we\u2019re exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs. We are also advancing AVTX-010, a long-acting next-generation anti-IL-1\u03b2 mAb designed to extend dosing intervals and build upon the differentiated profile established by abdakibart. For more information about Avalo, please visit www.avalotx.com.<\/p>\n

\n About Abdakibart <\/strong>\n <\/p>\n

Abdakibart is a humanized monoclonal antibody (IgG4) that binds to interleukin-1\u03b2 (IL-1\u03b2) with high affinity and neutralizes its activity. IL-1\u03b2 is a pro-inflammatory cytokine that plays a central role in the pathogenesis of a wide range of human diseases.1 It activates immune cells that generate proinflammatory cytokines, including IL-6, TNF-\u03b1, and IL-17. Dysregulated IL-1\u03b2 signaling is a major driver of inflammation, contributing to the progression of autoimmune disorders. IL-1\u03b2 inhibition has proven effective in multiple immune-mediated inflammatory diseases. 1-3<\/sup><\/p>\n

References:1<\/sup>Dinarello CA. Immunol Rev. 2018;281(1):8-27. 2<\/sup>Kany S et al. Int J Mol Sci. 2019;20(23):6008. 3<\/sup>Kimball AB et al. Presented at: American Academy of Dermatology; March 8-12, 2024; San Diego, CA.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

This press release includes forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond our control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to our plans, objectives, projections, expectations and intentions and other statements identified by words such as \u201cprojects,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201ccontinue,\u201d \u201cseeks,\u201d \u201caims,\u201d \u201cpredicts,\u201d \u201cbelieves,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cestimates,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cpotential,\u201d or similar expressions (including their use in the negative), or by discussions of future matters such as: therapeutic potential, clinical benefits and safety profiles of abdakibart (AVTX-009); plans to advance abdakibart into a registrational phase 3 program; plans to commercialize abdakibart; expectations regarding timing, success and data announcements of ongoing preclinical studies and clinical trials; drug development costs, reliance on investigators and enrollment of patients in clinical trials; and our plans to develop and commercialize our current and any future product candidates and the implementation of our business model and strategic plans for our business.<\/p>\n

Any forward-looking statements are based on management\u2019s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements including, without limitation, risks associated with: the timing and anticipated results of our current and future preclinical studies and clinical trials, supply chain, strategy and future operations; the delay of any current and future preclinical studies or clinical trials or the development of our product candidates; the risk that the results of prior preclinical studies and clinical trials may not be predictive of future results in connection with current or future preclinical studies and clinical trials, including those for abdakibart; the timing and outcome of any interactions with regulatory authorities; obtaining, maintaining and protecting our intellectual property; the availability of funding sufficient for our operating expenses and capital expenditure requirements, reliance on key personnel; regulatory risks; general economic and market risks and uncertainties, including those caused by the war in Ukraine and the Middle East; and those other risks detailed in our filings with the Securities and Exchange Commission, available at www.sec.gov. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. In addition, any forward-looking statements represent our view only as of today and should not be relied upon as representing its views as of any subsequent date. You should not rely upon forward-looking statements as predictions of future events and actual results or events could differ materially from the plans, intentions and expectations disclosed herein. Except as required by applicable law, we expressly disclaim any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.<\/p>\n

\n For media and investor inquiries<\/strong>\n <\/p>\n

Christopher Sullivan, CFO<\/p>\n

Avalo Therapeutics, Inc.<\/p>\n

ir@avalotx.com<\/p>\n

410-803-6793<\/p>\n

\n or<\/em>\n <\/p>\n

Meru Advisors<\/p>\n

Lauren Glaser<\/p>\n

lglaser@meruadvisors.com<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

WAYNE, Pa., June 23, 2026 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1\u03b2 pathway for immune-mediated inflammatory diseases, today announced the appointment of Ron Philip to its Board of Directors. Mr. Philip brings more than 30 years of biopharmaceutical leadership to the Board, with a deep background in commercial and strategic execution, including guiding multiple companies through product launches and billion dollar exits. \u201cWe are thrilled to welcome Ron to the Board at this pivotal time for Avalo following our positive Phase 2 LOTUS topline results and transformative financing,\u201d said Garry Neil, MD, Chief Executive Officer of Avalo Therapeutics. \u201cRon\u2019s strategic and commercial expertise, including his proven success … <\/p>\n

Continue reading “Avalo Therapeutics Appoints Ron Philip to Board of Directors”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-974581","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAvalo Therapeutics Appoints Ron Philip to Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-appoints-ron-philip-to-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avalo Therapeutics Appoints Ron Philip to Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WAYNE, Pa., June 23, 2026 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1\u03b2 pathway for immune-mediated inflammatory diseases, today announced the appointment of Ron Philip to its Board of Directors. Mr. Philip brings more than 30 years of biopharmaceutical leadership to the Board, with a deep background in commercial and strategic execution, including guiding multiple companies through product launches and billion dollar exits. \u201cWe are thrilled to welcome Ron to the Board at this pivotal time for Avalo following our positive Phase 2 LOTUS topline results and transformative financing,\u201d said Garry Neil, MD, Chief Executive Officer of Avalo Therapeutics. \u201cRon\u2019s strategic and commercial expertise, including his proven success … Continue reading "Avalo Therapeutics Appoints Ron Philip to Board of Directors"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-appoints-ron-philip-to-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-23T11:04:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MDcxMSM3NjcyNDUwIzIwMTkzMjA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-appoints-ron-philip-to-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-appoints-ron-philip-to-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Avalo Therapeutics Appoints Ron Philip to Board of Directors\",\"datePublished\":\"2026-06-23T11:04:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-appoints-ron-philip-to-board-of-directors\\\/\"},\"wordCount\":1176,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-appoints-ron-philip-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1MDcxMSM3NjcyNDUwIzIwMTkzMjA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-appoints-ron-philip-to-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-appoints-ron-philip-to-board-of-directors\\\/\",\"name\":\"Avalo Therapeutics Appoints Ron Philip to Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-appoints-ron-philip-to-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-appoints-ron-philip-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1MDcxMSM3NjcyNDUwIzIwMTkzMjA=\",\"datePublished\":\"2026-06-23T11:04:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-appoints-ron-philip-to-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-appoints-ron-philip-to-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-appoints-ron-philip-to-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1MDcxMSM3NjcyNDUwIzIwMTkzMjA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1MDcxMSM3NjcyNDUwIzIwMTkzMjA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-appoints-ron-philip-to-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Avalo Therapeutics Appoints Ron Philip to Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Avalo Therapeutics Appoints Ron Philip to Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-appoints-ron-philip-to-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Avalo Therapeutics Appoints Ron Philip to Board of Directors - Market Newsdesk","og_description":"WAYNE, Pa., June 23, 2026 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1\u03b2 pathway for immune-mediated inflammatory diseases, today announced the appointment of Ron Philip to its Board of Directors. Mr. Philip brings more than 30 years of biopharmaceutical leadership to the Board, with a deep background in commercial and strategic execution, including guiding multiple companies through product launches and billion dollar exits. \u201cWe are thrilled to welcome Ron to the Board at this pivotal time for Avalo following our positive Phase 2 LOTUS topline results and transformative financing,\u201d said Garry Neil, MD, Chief Executive Officer of Avalo Therapeutics. \u201cRon\u2019s strategic and commercial expertise, including his proven success … Continue reading \"Avalo Therapeutics Appoints Ron Philip to Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-appoints-ron-philip-to-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-23T11:04:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MDcxMSM3NjcyNDUwIzIwMTkzMjA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-appoints-ron-philip-to-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-appoints-ron-philip-to-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Avalo Therapeutics Appoints Ron Philip to Board of Directors","datePublished":"2026-06-23T11:04:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-appoints-ron-philip-to-board-of-directors\/"},"wordCount":1176,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-appoints-ron-philip-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MDcxMSM3NjcyNDUwIzIwMTkzMjA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-appoints-ron-philip-to-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-appoints-ron-philip-to-board-of-directors\/","name":"Avalo Therapeutics Appoints Ron Philip to Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-appoints-ron-philip-to-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-appoints-ron-philip-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MDcxMSM3NjcyNDUwIzIwMTkzMjA=","datePublished":"2026-06-23T11:04:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-appoints-ron-philip-to-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-appoints-ron-philip-to-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-appoints-ron-philip-to-board-of-directors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MDcxMSM3NjcyNDUwIzIwMTkzMjA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MDcxMSM3NjcyNDUwIzIwMTkzMjA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-appoints-ron-philip-to-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Avalo Therapeutics Appoints Ron Philip to Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/974581","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=974581"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/974581\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=974581"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=974581"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=974581"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}